870PDEfficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap). (23rd October 2018) - Negrier, S; Rioux-Leclercq, N; Ravaud, A; Gravis, G; Geoffrois, L; Chevreau, C M; Rolland, F; Blanc, E; Segura-Ferlay, C; Perol, D; Gross Goupil, M; Dermeche, S; et al.